130 related articles for article (PubMed ID: 38859770)
1. STRN::ALK, a novel fusion to foetal lung interstitial tumour.
Paoli C; Di Mauro I; Coulomb A; Benadiba J; Lecompte JF; Dadone-Montaudié B; Burel-Vandenbos F
Histopathology; 2024 Jun; ():. PubMed ID: 38859770
[No Abstract] [Full Text] [Related]
2.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract][Full Text] [Related]
4. A Rare
Yang Y; Qin SK; Zhu J; Wang R; Li YM; Xie ZY; Wu Q
Mayo Clin Proc Innov Qual Outcomes; 2017 Jul; 1(1):111-116. PubMed ID: 30225407
[TBL] [Abstract][Full Text] [Related]
5. STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report.
Zhang L; Xiao P; Meng F; Zhong D
Curr Oncol; 2022 Sep; 29(10):6749-6753. PubMed ID: 36290807
[TBL] [Abstract][Full Text] [Related]
6. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
[TBL] [Abstract][Full Text] [Related]
7. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract][Full Text] [Related]
8. Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.
Nikitski AV; Rominski SL; Wankhede M; Kelly LM; Panebianco F; Barila G; Altschuler DL; Nikiforov YE
Am J Pathol; 2018 Nov; 188(11):2653-2661. PubMed ID: 30125543
[TBL] [Abstract][Full Text] [Related]
9. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.
Zhu L; Ma S; Xia B
Front Oncol; 2022; 12():1009076. PubMed ID: 36439495
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
11. Ciliated Muconodular Papillary Tumors of the Lung Harboring
Zhang X; Yuan W; Luo R; Luan L; Huang J; Lu S; Sujie A; Hou Y
Int J Surg Pathol; 2024 Feb; ():10668969241226707. PubMed ID: 38321754
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Identification of Two Rare Fusions,
Zeng H; Li Y; Wang Y; Huang M; Zhang Y; Tian P; Li W
Front Oncol; 2021; 11():722843. PubMed ID: 34485156
[TBL] [Abstract][Full Text] [Related]
13. Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib.
Song GQ; Li YZ; Kong W; Hu GQ
Front Oncol; 2023; 13():1235679. PubMed ID: 37810968
[TBL] [Abstract][Full Text] [Related]
14. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.
Wu X; Wang Q; Xu X
Front Oncol; 2023; 13():1156329. PubMed ID: 37152028
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.
Li X; Zheng J; Li X; Chen Y; Liu K; Li F; Lu Z
Front Oncol; 2023; 13():1252221. PubMed ID: 37869075
[TBL] [Abstract][Full Text] [Related]
17. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
18. Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion.
Rooper LM; Thompson LDR; Gagan J; Oliai BR; Weinreb I; Bishop JA
Head Neck Pathol; 2021 Mar; 15(1):179-185. PubMed ID: 32661669
[TBL] [Abstract][Full Text] [Related]
19. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
20. Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males.
Rosebush MS; Smith MH; Cordell KG; Callahan N; Zaid W; Gagan J; Bishop JA
Head Neck Pathol; 2024 Mar; 18(1):26. PubMed ID: 38526831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
